Copyright
©2011 Baishideng Publishing Group Co.
World J Cardiol. Jun 26, 2011; 3(6): 169-176
Published online Jun 26, 2011. doi: 10.4330/wjc.v3.i6.169
Published online Jun 26, 2011. doi: 10.4330/wjc.v3.i6.169
First author | Type of study | n | Drug used | Termination of arrhythmia | Other complications | TdP | Survival |
Human studies | |||||||
Amino et al[25] | Out of hospital cardiac arrest with refractory VT/VF to epinephrine and lidocaine | 32 | 11 nifekalant | 9 (82%) | 0 | 2 (18%) | |
21 lidocaine | 4 (19%) | 0 | 0 | ||||
Yoshioka et al[26] | Out of hospital cardiac arrest with refractory VT/VF to epinephrine and lidocaine | 36 | 12 nifekalant | 9 (75%) | 4 sinus suppression (sinus bradycardia and sinus pause) | 0 | 2 (17%) (24 h) |
24 lidocaine and magnesium and procainamide if necessary | 4 (17%) | ||||||
In hospital cardiac arrest with refractory VT/VF to epinephrine and lidocaine | 29 | 9 nifekalant | 8 (89%) | 0 sinus suppression (sinus bradycardia and sinus pause) | 1 | 4 (44%) (24 h) | |
20 lidocaine and magnesium and procainamide if necessary | 15 (75%) | ||||||
Tahara et al[27] | Out of hospital cardiac arrest with refractory VF to pinephrine | 120 | 55 nifekalant | 0 | 37 (67%) (hospital admission) | ||
29 (53%) (24 h) | |||||||
65 lidocaine | 0 | 24 (37%) (hospital admission) | |||||
20 (31%) (24 h) | |||||||
Igarashi et al[28] | Out of hospital cardiac arrest (VF) | 22 | 8 nifekalant | 5 (61.5%) | |||
14 lidocaine | 2 (14.3%) | ||||||
Yasuda et al[29] | Out of hospital cardiac arrest with refractory VT/VF to epinephrine | 14 | 14 nifekalant | 12 (86%) | 1 | 11 (79%) (hospital admission) | |
Shiga et al[30] | In hospital cardiac arrest with refractory VT/VF | 55 | 27 nifekalant | 22 (81%) | 0 Asystole 2 PEA 1 QT>0.55 | 0 | 13 (48%) (1-mo survival) |
12 (44%) (survival to discharge) | |||||||
28 lidocaine | 15 (54%) | 7 Asystole 1 PEA 0 QT>0.55 | 0 | 9 (32%) (1-mo survival) | |||
8 (29%) (survival to discharge) | |||||||
Amino et al[31] | Out of hospital cardiac arrest with refractory VF | 30 | 15 nifekalant | 7 (47%) | 0 Thyroid dysfunction | 0 | 7 (47%) (hospital admission) |
4 (27%) (survival to discharge) | |||||||
15 amiodarone | 10 (67%) | 1 Thyroid dysfunction | 0 | 10 (67%) (hospital admission) | |||
8 (53%) (survival to discharge) | |||||||
Animal studies | |||||||
Ji et al[32] | 4 min of untreated VF | 36 | 12 saline | 7 (58.3%) ROSC | 0 | 2 (17%) (24 h) | |
12 nifekalant | 12 (100%) ROSC | 1 | 8 (67%) (24 h) | ||||
12 amiodarone | 12 (100%) ROSC | 0 | 9 (75%) (24 h) |
- Citation: Pantazopoulos IN, Troupis GT, Pantazopoulos CN, Xanthos TT. Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias. World J Cardiol 2011; 3(6): 169-176
- URL: https://www.wjgnet.com/1949-8462/full/v3/i6/169.htm
- DOI: https://dx.doi.org/10.4330/wjc.v3.i6.169